Rekvina Labs Ltd
₹ 41.7
-0.67%
21 Aug
- close price
- Market Cap ₹ 46.4 Cr.
- Current Price ₹ 41.7
- High / Low ₹ 46.6 / 6.75
- Stock P/E
- Book Value ₹ -1.02
- Dividend Yield 0.00 %
- ROCE -333 %
- ROE %
- Face Value ₹ 5.00
Pros
- Promoter holding has increased by 35.7% over last quarter.
Cons
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.08 | 0.03 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 | 1.27 | 1.94 | |
| 0.05 | 0.03 | 0.12 | 0.05 | 0.10 | 0.15 | 0.06 | 0.04 | 0.00 | 0.02 | 0.14 | 1.52 | 2.27 | |
| Operating Profit | 0.03 | 0.00 | -0.06 | -0.05 | -0.10 | -0.15 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 |
| OPM % | 37.50% | 0.00% | -100.00% | -19.69% | -17.01% | ||||||||
| 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.03 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 |
| Tax % | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| 0.02 | 0.00 | -0.06 | -0.02 | -0.08 | 0.00 | -0.06 | -0.08 | 0.00 | -0.02 | -0.14 | -0.25 | -0.33 | |
| EPS in Rs | 0.02 | 0.00 | -0.05 | -0.02 | -0.07 | 0.00 | -0.05 | -0.07 | 0.00 | -0.02 | -0.12 | -0.21 | -0.27 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 62% |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves | -2.33 | -2.45 | -2.51 | -2.53 | -2.61 | -2.86 | -2.92 | -3.00 | -3.00 | -3.21 | -3.35 | -4.24 |
| 0.00 | 0.01 | 0.01 | 0.17 | 0.21 | 0.00 | 0.00 | 0.00 | 0.08 | 0.04 | 0.25 | 1.47 | |
| 0.09 | 0.09 | 0.13 | 0.14 | 0.19 | 0.13 | 0.15 | 0.18 | 0.11 | 0.17 | 0.12 | 0.95 | |
| Total Liabilities | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.19 |
| 0.27 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.15 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.00 | 0.00 | 0.00 |
| 0.45 | 0.46 | 0.44 | 0.59 | 0.60 | 0.08 | 0.04 | -0.01 | 0.00 | 0.01 | 0.03 | 1.19 | |
| Total Assets | 0.77 | 0.66 | 0.64 | 0.79 | 0.80 | 0.28 | 0.24 | 0.19 | 0.20 | 0.01 | 0.03 | 1.19 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 | |
| 0.01 | 0.02 | 0.07 | -0.07 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.00 | 0.01 | 0.00 | 0.16 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.21 | 0.58 | |
| Net Cash Flow | 0.00 | 0.00 | 0.03 | 0.10 | 0.01 | -0.01 | -0.01 | 0.00 | 0.01 | 0.00 | 0.02 | -0.01 |
| Free Cash Flow | -0.01 | -0.02 | -0.04 | 0.01 | -0.02 | -0.01 | -0.01 | -0.04 | 0.01 | -0.01 | -0.19 | -0.59 |
| CFO/OP | -33% | 67% | -20% | 20% | 7% | 17% | 50% | 50% | 136% | 236% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | 0.00 | |||||||
| Inventory Days | 0.00 | 0.00 | ||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 1,003.75 | 3,041.67 | 1,703.33 | 0.00 | 0.00 | |||||||
| Working Capital Days | 1,460.00 | 4,015.00 | 1,460.00 | -1,642.50 | -106.34 | |||||||
| ROCE % | 4.51% | 0.00% | -11.11% | -3.45% | -12.70% | -50.00% | -160.00% | 0.00% | -333.33% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Number of board meetings held count |
|
||||||||
| BSE trading suspension status status (1=Suspended, 0=Active) |
|||||||||
| Number of permanent employees on the rolls count |
|||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
- Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
-
Clarification On Price Movement
- Rekvina Labs clarifies no undisclosed price-sensitive information behind recent share price movement.
- FINANCIAL RESULTS QTR1
-
Board Meeting Outcome for OUTCOME OF BOARD MEETING
- Board approved Q1 FY2026-27 unaudited results and appointed Surbhit Shah as Chairman on 13 August 2026.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from bse
-
Annual Report 2012
from bse
-
Annual Report 2011
from bse
Delisting & Relisting
Trading in the Company’s equity shares, earlier suspended by the BSE due to non-compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015[1][2], has been revoked with effect from January 07, 2026. Pursuant to SEBI Master Circular dated November 11, 2024, and upon compliance with applicable requirements, including payment of annual listing fees, trading in the Company’s securities has resumed in the “XT” group[3] and shall be included under the “X” group with effect from January 20, 2026.[4]